Non-invasive exosomal diagnostic screen for the detection of heart transplant rejection
- Summary
- This technology utilizes exosomal protein profiling to non-invasively determine the risk of heart transplant rejection.
- Technology Benefits
- Non-invasiveWell-established extraction and analysis methodsFewer risks and contraindications relative to biopsyEarlier detection of rejectionExosomal contents are remarkably stable, reducing the risk of sample degradation compared to mRNA Cost-effective
- Technology Application
- Method to assess probability of cardiac allograft rejectionBiomarkers may aid detection of other cardiac disease statesBiomarkers could be potential therapeutic targetsPredicting allograft success in pre-transplant heart failure patients
- Detailed Technology Description
- None
- *Abstract
-
None
- *Inquiry
- Joan MartinezColumbia Technology VenturesTel: (212) 854-8444Email: TechTransfer@columbia.edu
- *IR
- CU15292
- *Principal Investigator
-
- *Publications
- Kennel PJ, Maldonado D, Givens R, Brunjes D, Castillero E, Chen E, George I, Mancini D, Schulze PC. “Serum Exosomal Protein Profiling for the Non-invasive Detection of Cardiac Allograft Rejection” Circulation. 2015 Nov 10; 132(Suppl 3): A16438.Kennel PJ, Givens R, Brunjes D, Chen E, Castillero E, Takayama H, Naka Y, George I, Mancini D, Schulze PC. Serum-Derived Exosomal Proteome Analysis of Patients With Heart Failure and After Heart Transplantation. J Heart Lung Transplant. 2015 April 34; 4(Supplement): S301.Tech Ventures Reference:IR CU15292Licensing Contact: Joan Martinez
- Country/Region
- USA
For more information, please click Here
